A Pfizer win in a heated anti-kickback case could lead to a ‘gold rush’ of biopharma companies subsidizing Medicare drugs, government says
Pfizer on Tuesday made the case for why it should be able to subsidize the cost of one of its rare disease drugs for some Medicare beneficiaries, but government lawyers warned of a “gold rush” of similar subsidies from biopharma companies if the court rules in Pfizer’s favor.
The District Court for the Southern District of New York on Tuesday heard oral arguments from both Pfizer and the government over whether the company can help poorer Medicare patients afford the company’s rare disease drug tafamidis, which comes with a $225,000 list price for a single year’s supply, of which Medicare beneficiaries have to pay about $13,000 annually.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
